Scientists create bone material from human stem cells to improve patient's welfare

Bone defects, like a damaged femoral head, are usually replaced by metal implants. This has many disadvantages, but now scientists in Germany have created bone material from human stem cells that could bring significant improvement to the patient's welfare.

Scientists in Würzburg, in Germany, have created living bone material from human stem cells in their laboratory. The discipline is called tissue engineering and the aim of the scientists is to produce the perfect substitute for bone transplantation.  

This new approach in bone regeneration may have the flavour of Frankenstein's methods, but it has a lot of advantages compared to traditional materials used in operations like hip replacements. Currently, these bone defects are mainly replaced with metal implants, which usually last only for ten to fifteen years before they are worn out. Heike Walles, bio engineer and coordinator of the European research project VascuBone, believes that her method of combining human cells with scaffolds and bone substitutes could become a routine procedure in the future and provide a perfect alternative to the current best practices.

Thorsten Gehrke, medical director of Europe's largest endocrinology clinic in Hamburg, is still skeptical whether human bones grown in the lab could provide enough replacement material, but he says that such material would be a blessing for every patient.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Experimental drug RK-33 shows promise in treating breast cancer bone metastasis